Benzinga··Vandana SinghAstraZeneca's Prostate Drug Wins FDA Panel Backing While Breast Cancer Candidate Falters
AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.
AZNFDA approvalbreast cancer